HEZE PHARMACEUTICAL Visits MOMED BIOTECH to Explore New Opportunities for Pharmaceutical Innovation and Collaboration
On January 12, 2026, a delegation led by Wei Bin Jiang, Deputy General Manager of HEZE PHARMACEUTICAL, visited MOMED BIOTECH. The delegation held in-depth discussions with Chen Bai, Chairman of MOMED BIOTECH, and the core team on multiple dimensions including drug R&D, capital cooperation, and business synergy, laying a solid foundation for future in-depth strategic cooperation.
During the meeting, MOMED BIOTECH Chairman Chen Bai introduced the company’s AI-driven drug discovery platform and key pipeline strategies. He highlighted AI’s transformative role in target identification, compound optimization, and clinical trial design, emphasizing its ability to accelerate R&D and reduce costs—especially in complex disease areas such as oncology and neurology.
Mr. Jiang expressed strong recognition of MOMED BIOTECH’s AI capabilities and presented HEZE PHARMACEUTICAL’s integrated R&D service system, which covers pharmaceutical research, clinical development, regulatory affairs, CDMO/CMO services, and technology transfer. He noted the significant complementarity between the two companies, with MOMED BIOTECH’s AI strengths perfectly matching HEZE PHARMACEUTICAL’s full-chain R&D and industrialization expertise.
Both sides engaged in in-depth discussions on technology collaboration, joint R&D, pipeline sharing, and platform co-construction. They agreed that combining MOMED BIOTECH’s AI-driven discovery platform with HEZE PHARMACEUTICAL’s development and manufacturing capabilities would create powerful synergies, accelerating the development of novel therapeutics and enhancing product competitiveness.
At the conclusion of the visit, both parties expressed a strong desire to deepen cooperation. HEZE PHARMACEUTICAL extended an invitation to MOMED BIOTECH’s core team for a follow-up visit to further explore specific collaboration projects.
Looking ahead, the two companies will continue to advance joint initiatives in innovative drug R&D, platform building, and technology transfer. By leveraging the “AI + full industry chain” model, they aim to drive pharmaceutical innovation, deliver better treatment options to patients, and contribute to the high-quality development of the healthcare industry.
END
HEZE PHARMACEUTICAL’s core business covers pharmaceutical research, clinical research, TCM research, third-party testing, regulatory affairs, and S-CDMO/CMO services, being one of China’s largest comprehensive pharmaceutical R&D institutions. It has over 1,000 project experiences across liver diseases, gynecology, diabetes, oncology and other areas.
MoMed Biotech (www.momed.com.cn) is the world's first biotechnology company that conducts innovative drug research and development by taking the mechanism research of drug targets as the driving force and combining advanced artificial intelligence technology. MoMed uses the Nobel Prize-winning computational biology method to study the working mechanism of target proteins, thus achieving a methodological leap at the AI data end. The MechGen drug research and development platform of MoMed Biotech integrates the industry-leading computational biology and AI drug design technologies, providing a variety of preclinical drug discovery services for the industry.
分享:
Hot News
- 2024-10-31
- 2024-11-22
- 2025-01-16
-
2025-01-17
MoMed Biotech's Moments on CCTV! Catch the Wonderful Highlights in Advance!